A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Inclusion Criteria: * Willing to sign written informed consent; * Male or female, aged 18-70 years; Adolescent participants with chronic HDV infection: Male or female, age ≥12 years and \<18 years at the time of signing the informed consent form (ICF)/assent; * Chronic HDV history with at least 6 months; For participants who are also recommended for anti-HBV therapy prior first-line NrtIs treatment (ETV, TDF, TAF) should be at least 12 weeks before the planned start of study treatment, or participant is willing to initiate first-line NrtIs treatment; HBV DNA suppressed; * HDV RNA ≥500 IU/mL at screening; * ALT \>1×ULN and \<10×ULN at screening; * Able to communicate well and comply with protocol. Exclusion Criteria: * Concomitant decompensated cirrhosis; * Previous or current HCC or suspicion for HCC; * Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis, autoimmune liver disease or other hereditary liver diseases, drug-induced liver disease or other clinically significant chronic liver diseases not caused by HDV/HBV; * Participants with active hepatitis C infection, or HIV infection; * History of other malignancies other than HCC; * Clinically significant ECG abnormalities at screening, which is deemed unsuitable for enrollment per investigator's discretion; * Alcohol abuse or drug addiction within 1 year; * Participants who have participated in clinical trials of any drug or medical device within 1 month before randomization; * Pregnant, lactating women, or women of childbearing potential with a positive pregnancy test; * Any other clinically significant abnormal lab result, severe acute/chronic medical/psychiatric condition, concomitant serious systemic disease.